Slide 1: Creating & Developing Companies To Improve the Human Condition
Creating & Developing Companies To Improve the Human Condition Financial Highlights Q1 2016 May 2016
Slide 2: Legal Disclaimer
Legal Disclaimer IMPORTANT NOTICE This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 3: Contents
Contents I. Overview & Business Model II. Financial Highlights Balance Sheet Profit & Loss III. Portfolio Highlights IV. Q1 2016 Highlights V. Stock Information VI. Upcoming Events 3
Slide 4: I. Overview & Business Model
I. Overview & Business Model 4
Slide 5: Innovation Commercialization
Trendlines: Innovation Commercialization The Trendlines Group invents, discovers, invests in, and incubates life science companies in the fields of medical and agricultural technologies. Invest through Israeli Government- Franchised Incubators Invest in life sciences companies Internal Innovation Ce
Slide 6: Deal Flow to Exit
Trendlines: Deal Flow to Exit 6
Slide 7: II. Financial Highlights
II. Financial Highlights Balance Sheet Profit & Loss 7
Slide 8: Balance Sheet Summary
Trendlines: Balance Sheet Summary 31 March 2016 31 Dec 2015 Unaudited Audited US$’000 US$’000 ASSETS Total Current Assets 21,472 24,000 Key Financial Ratios Current Assets to Current Liabilities 6.53 Total Non-Current Assets 85,739 84,988 Total Assets 107,211 108,988 Total Assets to Total Liabilitie
Slide 9: Profit & Loss Summary
Trendlines: Profit & Loss Summary 31 March 2016 31 March 2015 Three months ended: Unaudited Unaudited US$’000 US$’000 Total income 1,140 3,160 Total expenses before non-recurring, non-cash expenses related to discount on pre-IPO RCL upon IPO conversion 2,633 2,218 Income/(loss) before income taxes (
Slide 10: III. Portfolio Highlights
III. Portfolio Highlights 10
Slide 11: Growth of Portfolio Value
Trendlines: Growth of Portfolio Value Portfolio Values US$ 000 100000 FV of investments in consolidated non-operating subsidiaries 90000 85,776 86,899 77,494 Fair Value ("FV") of investments in companies 80000 74,639 accounted for under the equity method 70000 Portfolio Value 60000 47,499 50000 4000
Slide 12: Building Value Over Time
Trendlines: Building Value Over Time One of our 10 most valuable portfolio companies as at As at 31 March 2016; 19 written-off portfolio companies and 2 companies established before 31 March 2016. September 2007 not listed. IPO indicates reverse mergers into public companies. 12
Slide 13: Most Valuable Portfolio Companies
Trendlines: 10 Most Valuable Portfolio Companies Total estimated fair market value of our 10 most valuable portfolio companies: approximately US$62.2*million, representing 71.6% of total portfolio value of approximately US$86.9*million as at 31 March 2016. % Owned Company Name Initial Investment (Fu
Slide 14: IV. Q1 2016 Highlights
IV. Q1 2016 Highlights 14
Slide 15: Corporate News Q1 2016
Trendlines: Corporate News Q1 2016 • Definitive cooperation agreement signed with B. Braun Melsungen AG. • Trendlines Labs • Signed framework agreement with large Japanese medtech multinational. • Received new order from large U.S. medtech multinational. • Moshe Katzenelson named VP International In
Slide 16: Companies & Incubator News Q1 2016
Trendlines: Companies & Incubator News Q1 2016 • New Company established: AquiNovo Ltd. • Significant raises: • Saturas Ltd. about US$1 million • Magdent Ltd. about US$800,000 • E.T.View Medical Ltd. reported 2015 sales increased 31% compared to 2014 to NIS 7.74 million • Trendlines Agtech franchise
Slide 17: Significant Events Since March 2016
Trendlines: Significant Events Since 31 March 2016 • Bayer AG signs agreement committing to invest US$10 million in the Bayer Trendlines Ag Innovation Fund. • Arcuro Medical Ltd. raises US$500,000 from Chinese medical device company Naton Medical Group Ltd. 17
Slide 18: V. Stock Information
V. Stock Information 18
Slide 19: Stock Overview & Peers
Trendlines: Stock Overview & Peers As at 6 May 2016 SGD Last Price 0.205 IPO Price 0.330 52 Wk High 0.395 52 Wk Low 0.133 Market Cap 104.3 million Shares Outstanding 508.8 million Free Float 365.8 million Price to Portfolio (FMV)* Allied Minds (LSE:ALM) 2.06 Imperial Innovations (AIM:IVO) 1.86 IP Gr
Slide 20: VI. Upcoming Events
VI. Upcoming Events 20
Slide 21: Events Around the World
Events Around the World Trendlines Singapore Medical Company Showcase 8 Companies. 5 Cities. 5 Days. Singapore, Beijing, Shanghai, Shenzhen, Hong Kong 4-8 July 2016 4th ANNUAL Showcasing the Israeli agtech ecosystem Weizmann Institute of Science Rehovot, Israel 27 September 2016 21
Slide 22: Creating & Developing Companies To Improve the Human Condition
Creating & Developing Companies To Improve the Human Condition Todd Dollinger, Chairman & CEO Steve Rhodes, Chairman & CEO +972.72.260.7000 | www.trendlines.com Judith Kleinman, Director Investor Relations & Corporate Communications judith@trendlines.com 11 May 2016